封面
市場調查報告書
商品編碼
2177391

多價流感疫苗市場:全球市場預測,2026-2032年

Multivalent Influenza Vaccines Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,多價流感疫苗市場將成長至 158.1 億美元,複合年成長率為 10.44%。

主要市場統計數據
基準年 2025 78.9億美元
預計年份:2026年 87.2億美元
預測年份 2032 158.1億美元
複合年成長率 (%) 10.44%

多價流感疫苗:概述

多價流感疫苗將針對多種流感病毒株的保護作用結合在單一製劑中。其研發和推廣受到季節性流感病毒株變異、公共衛生政策、免疫基礎設施、生產能力、監管要求以及對不同年齡層和風險人群提高保護效果的需求等因素的影響。本執行摘要概述了影響市場的關鍵結構性、技術性、區域性、群體特定性和國家層面的考量因素,但不提供市場估算或預測。

股市演變和疫苗接種政策正在重塑市場環境。

由於流感病毒的不斷變異,市場格局正在發生變化,因此需要透過既定的全球監測和病毒株選擇流程來更新疫苗配方。公共衛生機構日益重視擴大目標族群、及時進行季節性疫苗接種、為老年人和有基礎疾病的人群接種疫苗,並透過藥局、基層醫療、職場免疫計畫和社區等管道提高疫苗可及性。生產穩定性、基於雞蛋和細胞培養的生產方法的選擇、佐劑的使用、冷鏈的可靠性以及監管機構之間的協調仍然是實際推廣的關鍵因素。

人工智慧正在提升監控、設計和營運能力。

人工智慧可以透過識別流行病學、基因組學、臨床和污水數據中的模式來輔助流感監測,但此類應用需要嚴格的檢驗和代表性的資料集。機器學習工具可以幫助進行病毒株鑑定、抗原分析、候選疫苗優先排序、臨床試驗規劃、需求管理和不利事件監測。雖然這些協同作用可以加速證據產生並實現更快速的應對,但在人工智慧的輸出能夠影響公共衛生決策之前,人工監督、透明的績效評估、資料管治、網路安全和監管課責仍然至關重要。

區域洞察:準備程度的差異會影響採用率和使用率。

北美地區擁有完善的季節性免疫接種計劃、廣泛的醫療服務網路以及強大的監管和生產能力,但不同地區和人群的疫苗接種率和可近性仍然存在差異。歐洲受益於協調的監測和成熟的公共衛生體系,但各國在報銷和採購慣例存在差異。亞太地區一些經濟體已發展出先進的疫苗生態系統,而另一些經濟體在疫苗可及性和基礎設施方面仍存在顯著的未滿足需求。拉丁美洲受到公共部門採購、區域疾病監測和經濟狀況差異的影響。中東地區則反映了醫療體係能力、旅遊相關需求和免疫政策的差異。在非洲,資金籌措、供應連續性、冷鏈能力、監測覆蓋範圍以及將流感疫苗接種納入更廣泛的衛生計劃仍然具有重大影響。

集團洞察:政策協調與採購如何影響影響規模

東南亞國協的疾病監測成熟度、生產能力和疫苗可及性程度各不相同,因此區域協調和靈活的疫苗接種模式至關重要。金磚國家人口眾多且構成複雜,導致其優先事項廣泛,涵蓋國內生產和技術轉移、疫苗價格可負擔性以及公共部門覆蓋範圍等諸多方面。歐盟的優勢在於共用科學協調,同時又能維持各成員國不同的採購和報銷體系。七國集團成員國通常擁有健全的研究、監管和醫療衛生基礎設施,但仍需應對人口老化、公平性和疫苗信任等挑戰。海灣合作理事會成員國擁有相對完善的醫療衛生基礎設施,但人口流動性高且居住人口,因此季節性規劃協調的重要性更加凸顯。北約成員國尤其關注醫療衛生服務的連續性和應對跨境中斷的準備工作,但流感疫苗接種仍主要被視為公共衛生舉措,而非防禦性措施。

對不同國家的洞察:不同的醫療保健系統需要根據其具體情況量身定做的策略。

澳洲和日本擁有成熟的免疫系統和強大的監測能力,而韓國則將先進的醫療基礎設施與積極主動的季節性疫苗接種政策相結合。中國和印度在生產、研發和供應方面擁有相當的實力,但疫苗的可及性和計畫實施情況因地區而異。美國和加拿大擁有廣泛的醫療服務提供者和藥房網路,疫苗接種率取決於公眾的信任度、報銷機制和地方政策。巴西和墨西哥依靠大規模的公共衛生計畫和廣泛的區域合作。法國、德國、義大利、西班牙和英國在完善的監管和臨床環境下運作,但在目標族群選擇標準、採購、保險報銷和疫苗接種環境方面存在差異。俄羅斯的優先事項包括國內供應的穩定性、監測和全國範圍內的免疫接種實施,而這些工作的成效受地區和醫療體系覆蓋範圍的影響。

領導者指南:韌性、證據與建構公平的服務體系

行業領導者應根據​​徵兆和實際的季節性計劃,調整其庫存選擇、生產和庫存決策。他們還需要實現關鍵投入和生產平台的多元化,加強品管體系,並制定緊急時應對計畫以應對供應中斷。實證策略應涵蓋不同年齡層和風險組的療效、真實世界結果、合併療法、安全性以及在不同給藥環境下的表現。與公共衛生機構、醫療服務提供者、雇主、藥局和社區團體合作將有助於改善藥物可近性並建立信任。人工智慧投資應從明確控制的應用案例、檢驗的數據、人工審核和可衡量的營運結果著手。最後,各組織應根據當地的採購、報銷、監管和基礎設施情況制定相應的准入策略,而不是套用單一的全球模式。

調查方法:基於證據的市場促進因素和條件審查。

本執行摘要根據多價流感疫苗市場的既定範圍,相關人員對研究結果進行分類。研究洞察源自於成熟的公共衛生和監管理念,包括流感監測、季節性病毒株選擇、免疫規劃設計、臨床證據、生產考量以及醫療保健系統的可近性。區域、群體和國家層級的觀察結果以定性方式呈現,旨在區分結構性因素和短期波動。本摘要不包含市場規模估算、市場規模、市場佔有率、預測或公司特定聲明。

結論:廣泛的規劃必須輔以可靠的執行。

多價流感疫苗正處於不斷演變的病毒風險、週期性季節性需求、公共衛生政策、生物技術和醫療服務體係等許多因素交會的十字路口。其影響不僅取決於疫苗配方和臨床表現,還取決於及時選擇病毒株、建立穩健的生產系統、公平採購、可靠的資訊傳播以及確保「最後一公里」的供應。那些將科學嚴謹性與在地化適應、透明的證據以及負責任的數位化創新相結合的領導者,將更有能力支持有效的季節性免疫接種計劃。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:多價流感疫苗市場:依產品類型分類

  • 四價
    • 高劑量
      • 含有佐劑
      • 無佐劑配方
    • 標準劑量
  • 三價

第8章:多價流感疫苗市場:依疫苗類型分類

  • 失活
    • 分裂病毒
    • 次單元
  • 減毒活病毒疫苗
  • 重組

第9章:多價流感疫苗市場:依技術平台分類

  • 細胞培養類型
    • MDCK培養
    • 維羅文化
  • 蛋製品
  • 重組

第10章:多價流感疫苗市場:依給藥途徑分類

  • 皮內接種
  • 肌肉內部
  • 鼻腔

第11章:多價流感疫苗市場:依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第12章:多價流感疫苗市場:依最終用戶分類

  • 診所
  • 醫院
  • 藥局
  • 公共衛生組織

第13章:多價流感疫苗市場:依通路分類

  • 直接購買
  • 政府競標
  • 零售藥房
  • 批發分銷

第14章:多價流感疫苗市場:依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章:多價流感疫苗市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章:多價流感疫苗市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第18章:公司簡介

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BioNTech SE
  • CSL Limited
  • CureVac NV
  • Dynavax Technologies Corporation
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals Inc.
  • KM Biologics Co., Ltd.
  • Medicago Inc.
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novartis AG
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus USA, Inc.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited

第19章 主要專家

Product Code: MRR-4772A753A266

The Multivalent Influenza Vaccines Market is projected to grow by USD 15.81 billion at a CAGR of 10.44% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.89 billion
Estimated Year [2026] USD 8.72 billion
Forecast Year [2032] USD 15.81 billion
CAGR (%) 10.44%

Multivalent Influenza Vaccines: Executive Overview

Multivalent influenza vaccines combine protection against multiple influenza virus strains in a single formulation. Their development and adoption are shaped by seasonal strain evolution, public-health policy, immunization infrastructure, manufacturing capabilities, regulatory requirements, and the need to improve protection across different age and risk groups. This executive summary reviews the principal structural, technological, regional, group, and country-level considerations affecting the market without presenting market estimates or forecasts.

Strain Evolution and Immunization Policy Are Reshaping the Landscape

The landscape is being transformed by the continual evolution of circulating influenza viruses and the resulting need to update vaccine compositions through established global surveillance and strain-selection processes. Public-health agencies increasingly emphasize broader coverage, timely seasonal deployment, vaccination of older adults and people with underlying conditions, and improved access through pharmacies, primary care, occupational programs, and community channels. Manufacturing resilience, egg-based and cell-based production choices, adjuvant use, cold-chain reliability, and regulatory coordination remain central to practical deployment.

Artificial Intelligence Is Strengthening Surveillance, Design, and Operations

Artificial intelligence can support influenza surveillance by identifying patterns in epidemiological, genomic, clinical, and wastewater data, although these applications require rigorous validation and representative datasets. Machine-learning tools may assist strain characterization, antigenic analysis, candidate prioritization, clinical-trial planning, demand coordination, and adverse-event monitoring. The cumulative effect is potentially faster evidence generation and more responsive operations, but human oversight, transparent performance evaluation, data governance, cybersecurity, and regulatory accountability remain essential before AI-supported outputs influence public-health decisions.

Regional Insights: Uneven Preparedness Shapes Adoption and Access

North America is characterized by established seasonal immunization programs, broad provider networks, and substantial regulatory and manufacturing capabilities, while access and uptake can still vary by jurisdiction and population group. Europe benefits from coordinated surveillance and mature public-health systems, but national reimbursement and procurement practices differ. Asia-Pacific combines advanced vaccine ecosystems in some economies with major unmet access and infrastructure needs in others. Latin America is influenced by public-sector procurement, regional disease surveillance, and economic variability. The Middle East reflects differences in health-system capacity, travel-related demand, and immunization policy. Africa remains strongly shaped by financing, supply continuity, cold-chain capacity, surveillance coverage, and the integration of influenza vaccination into broader health programs.

Group Insights: Policy Coordination and Procurement Influence Scale of Impact

ASEAN countries face varied surveillance maturity, manufacturing capacity, and access conditions, making regional coordination and flexible delivery models important. BRICS members span large and diverse populations, with priorities ranging from domestic production and technology transfer to affordability and public-sector coverage. The European Union benefits from shared scientific coordination while retaining nationally distinct purchasing and reimbursement systems. G7 members generally possess strong research, regulatory, and health infrastructure, yet must address aging populations, equity, and vaccine confidence. GCC countries combine comparatively strong health infrastructure with high mobility and expatriate populations, increasing the value of coordinated seasonal planning. NATO members have an additional interest in continuity of healthcare operations and preparedness for cross-border disruptions, while influenza vaccination remains primarily a public-health rather than defense intervention.

Country Insights: Diverse Health Systems Require Tailored Strategies

Australia and Japan have mature immunization systems and strong surveillance capabilities, while South Korea combines advanced healthcare infrastructure with active seasonal vaccination policy. China and India present substantial manufacturing, research, and delivery capacity alongside significant regional variation in access and program implementation. The United States and Canada have broad provider and pharmacy channels, with uptake influenced by public confidence, reimbursement, and jurisdictional policy. Brazil and Mexico rely on large public-health programs and extensive regional coordination. France, Germany, Italy, Spain, and the United Kingdom operate within well-developed regulatory and clinical environments, but differ in eligibility rules, procurement, reimbursement, and delivery settings. Russia's priorities include domestic supply resilience, surveillance, and national immunization implementation, with outcomes affected by geography and health-system reach.

Actions for Leaders: Build Resilience, Evidence, and Equitable Delivery

Industry leaders should align strain-selection, manufacturing, and inventory decisions with surveillance signals and realistic seasonal timelines. They should diversify critical inputs and production platforms, strengthen quality systems, and maintain contingency plans for disruptions. Evidence strategies should address effectiveness across age and risk groups, real-world outcomes, coadministration, safety, and performance in different delivery settings. Partnerships with public-health agencies, providers, employers, pharmacies, and community organizations can improve access and confidence. AI investments should begin with clearly governed use cases, validated data, human review, and measurable operational outcomes. Finally, organizations should tailor access strategies to local procurement, reimbursement, regulatory, and infrastructure conditions rather than applying a single global model.

Research Methodology: Evidence-Based Review of Market Drivers and Conditions

This executive summary uses the defined multivalent influenza vaccine market scope and organizes findings across technology, epidemiology, policy, manufacturing, delivery, geography, and stakeholder groups. Insights are derived from established public-health and regulatory concepts, including influenza surveillance, seasonal strain selection, vaccination-program design, clinical evidence, production considerations, and health-system access. Regional, group, and country observations are presented qualitatively and are intended to distinguish structural conditions from short-term variation. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included.

Conclusion: Broader Coverage Must Be Matched by Reliable Implementation

Multivalent influenza vaccines sit at the intersection of evolving viral risk, recurring seasonal demand, public-health policy, biotechnology, and healthcare delivery. Their impact will depend not only on formulation and clinical performance, but also on timely strain decisions, resilient manufacturing, equitable procurement, trusted communication, and dependable last-mile access. Leaders that combine scientific discipline with regional adaptation, transparent evidence, and responsible digital innovation will be better positioned to support effective seasonal immunization programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Multivalent Influenza Vaccines Market, by Product Type

  • 7.1. Introduction
  • 7.2. Quadrivalent
    • 7.2.1. High Dose
      • 7.2.1.1. Adjuvanted
      • 7.2.1.2. Non Adjuvanted
    • 7.2.2. Standard Dose
  • 7.3. Trivalent

8. Multivalent Influenza Vaccines Market, by Vaccine Type

  • 8.1. Introduction
  • 8.2. Inactivated
    • 8.2.1. Split Virus
    • 8.2.2. Subunit
  • 8.3. Live Attenuated
  • 8.4. Recombinant

9. Multivalent Influenza Vaccines Market, by Technology Platform

  • 9.1. Introduction
  • 9.2. Cell Based
    • 9.2.1. MDCK Culture
    • 9.2.2. Vero Culture
  • 9.3. Egg Based
  • 9.4. Recombinant

10. Multivalent Influenza Vaccines Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intradermal
  • 10.3. Intramuscular
  • 10.4. Intranasal

11. Multivalent Influenza Vaccines Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Multivalent Influenza Vaccines Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Hospitals
  • 12.4. Pharmacy
  • 12.5. Public Health Agencies

13. Multivalent Influenza Vaccines Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Direct Purchase
  • 13.3. Government Tender
  • 13.4. Retail Pharmacy
  • 13.5. Wholesale Distribution

14. Multivalent Influenza Vaccines Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Multivalent Influenza Vaccines Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Multivalent Influenza Vaccines Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AstraZeneca plc
  • 18.2. Bharat Biotech International Limited
  • 18.3. BioNTech SE
  • 18.4. CSL Limited
  • 18.5. CureVac N.V.
  • 18.6. Dynavax Technologies Corporation
  • 18.7. GlaxoSmithKline plc
  • 18.8. Inovio Pharmaceuticals Inc.
  • 18.9. KM Biologics Co., Ltd.
  • 18.10. Medicago Inc.
  • 18.11. Merck & Co., Inc.
  • 18.12. Moderna Inc.
  • 18.13. Novartis AG
  • 18.14. Novavax Inc.
  • 18.15. Pfizer Inc.
  • 18.16. Sanofi S.A.
  • 18.17. Seqirus USA, Inc.
  • 18.18. Takeda Pharmaceutical Company Limited
  • 18.19. Zydus Cadila Limited

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Multivalent Influenza Vaccines Market, Years Considered for the Study
  • FIGURE 2. Global Multivalent Influenza Vaccines Market, Research Design
  • FIGURE 3. Global Multivalent Influenza Vaccines Market, Research Framework
  • FIGURE 4. Global Multivalent Influenza Vaccines Market, Data Triangulation
  • FIGURE 5. Global Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2025 vs 2032 (%)
  • FIGURE 11. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 15. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Multivalent Influenza Vaccines Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Multivalent Influenza Vaccines Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 19. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Multivalent Influenza Vaccines Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Multivalent Influenza Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Multivalent Influenza Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Multivalent Influenza Vaccines Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Multivalent Influenza Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Multivalent Influenza Vaccines Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Multivalent Influenza Vaccines Market Segmentation & Coverage
  • TABLE 2. Global Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global High Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global High Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global High Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Adjuvanted Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Adjuvanted Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Adjuvanted Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Non Adjuvanted Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Non Adjuvanted Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Non Adjuvanted Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Standard Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Standard Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Standard Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Trivalent Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Trivalent Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Trivalent Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 23. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Split Virus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Split Virus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Split Virus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 39. Global Cell Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Cell Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Cell Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global MDCK Culture Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global MDCK Culture Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global MDCK Culture Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Vero Culture Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Vero Culture Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Vero Culture Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Egg Based Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Egg Based Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Egg Based Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 55. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 65. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 75. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Public Health Agencies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Public Health Agencies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Public Health Agencies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 88. Global Direct Purchase Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Direct Purchase Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Direct Purchase Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global Government Tender Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Government Tender Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Government Tender Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global Wholesale Distribution Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Wholesale Distribution Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Wholesale Distribution Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 103. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 104. Asia-Pacific Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. North America Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. North America Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 115. North America Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 116. North America Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 117. North America Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 118. North America Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 119. North America Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 120. North America Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 121. North America Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 122. North America Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 123. North America Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. North America Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 125. Latin America Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Latin America Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 127. Latin America Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 128. Latin America Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 129. Latin America Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 130. Latin America Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 131. Latin America Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 132. Latin America Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 133. Latin America Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 134. Latin America Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 135. Latin America Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. Latin America Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 137. Europe Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 138. Europe Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 139. Europe Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 140. Europe Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 141. Europe Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 142. Europe Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 143. Europe Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 144. Europe Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 145. Europe Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 146. Europe Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 147. Europe Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 148. Europe Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 149. Middle East Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Middle East Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 151. Middle East Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 152. Middle East Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 153. Middle East Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 154. Middle East Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 155. Middle East Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 156. Middle East Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 157. Middle East Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 158. Middle East Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 159. Middle East Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. Middle East Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. Africa Multivalent Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 162. Africa Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. Africa Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 164. Africa Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 165. Africa Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 166. Africa Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 167. Africa Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 168. Africa Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 169. Africa Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 170. Africa Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 171. Africa Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Africa Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 173. Global Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. ASEAN Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 175. ASEAN Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 176. ASEAN Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 177. ASEAN Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 178. ASEAN Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 179. ASEAN Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 180. ASEAN Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 181. ASEAN Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 182. ASEAN Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 183. ASEAN Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 184. ASEAN Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. ASEAN Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. GCC Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 187. GCC Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 188. GCC Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 189. GCC Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 190. GCC Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 191. GCC Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 192. GCC Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 193. GCC Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 194. GCC Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. GCC Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 196. GCC Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 197. GCC Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. European Union Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. European Union Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 200. European Union Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 201. European Union Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 202. European Union Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 203. European Union Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 204. European Union Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 205. European Union Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 206. European Union Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 207. European Union Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 208. European Union Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. European Union Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 210. BRICS Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 211. BRICS Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 212. BRICS Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 213. BRICS Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 214. BRICS Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 215. BRICS Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 216. BRICS Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 217. BRICS Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 218. BRICS Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 219. BRICS Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 220. BRICS Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 221. BRICS Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 222. G7 Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 223. G7 Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 224. G7 Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 225. G7 Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 226. G7 Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 227. G7 Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 228. G7 Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 229. G7 Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 230. G7 Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 231. G7 Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 232. G7 Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 233. G7 Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. NATO Multivalent Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 235. NATO Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 236. NATO Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 237. NATO Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 238. NATO Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 239. NATO Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 240. NATO Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 241. NATO Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 242. NATO Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 243. NATO Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 244. NATO Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 245. NATO Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 246. Global Multivalent Influenza Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 247. United States Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 248. United States Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 249. United States Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 250. United States Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 251. United States Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 252. United States Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 253. United States Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 254. United States Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 255. United States Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 256. United States Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 257. United States Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 258. United States Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 259. Canada Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 260. Canada Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 261. Canada Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 262. Canada Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 263. Canada Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 264. Canada Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 265. Canada Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 266. Canada Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 267. Canada Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 268. Canada Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 269. Canada Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 270. Canada Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 271. Mexico Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 272. Mexico Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 273. Mexico Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 274. Mexico Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 275. Mexico Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 276. Mexico Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 277. Mexico Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 278. Mexico Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 279. Mexico Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 280. Mexico Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 281. Mexico Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 282. Mexico Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 283. Brazil Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 284. Brazil Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 285. Brazil Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 286. Brazil Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 287. Brazil Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 288. Brazil Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 289. Brazil Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 290. Brazil Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 291. Brazil Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 292. Brazil Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 293. Brazil Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. Brazil Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 295. United Kingdom Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 296. United Kingdom Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 297. United Kingdom Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 298. United Kingdom Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 299. United Kingdom Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 300. United Kingdom Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 301. United Kingdom Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 302. United Kingdom Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 303. United Kingdom Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 304. United Kingdom Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 305. United Kingdom Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 306. United Kingdom Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 307. Germany Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 308. Germany Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 309. Germany Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 310. Germany Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 311. Germany Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 312. Germany Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 313. Germany Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 314. Germany Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 315. Germany Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. Germany Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 317. Germany Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 318. Germany Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 319. France Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 320. France Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 321. France Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 322. France Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 323. France Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 324. France Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 325. France Multivalent Influenza Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 326. France Multivalent Influenza Vaccines Market Size, by Cell Based, 2017-2032 (USD Million)
  • TABLE 327. France Multivalent Influenza Vaccines Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 328. France Multivalent Influenza Vaccines Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 329. France Multivalent Influenza Vaccines Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 330. France Multivalent Influenza Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 331. Russia Multivalent Influenza Vaccines Market Size, 2017-2032 (USD Million)
  • TABLE 332. Russia Multivalent Influenza Vaccines Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 333. Russia Multivalent Influenza Vaccines Market Size, by Quadrivalent, 2017-2032 (USD Million)
  • TABLE 334. Russia Multivalent Influenza Vaccines Market Size, by High Dose, 2017-2032 (USD Million)
  • TABLE 335. Russia Multivalent Influenza Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
  • TABLE 336. Russia Multivalent Influenza Vaccines Market Size, by Inactivated, 2017-2032 (USD Million)
  • TABLE 337. Russ